Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl) naphthol sulfonamide type for the treatment of endometriosis

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3307-3318

  Henn, Claudia ^a,b   Einspanier, Almuth ^c   Marchais Oberwinkler, Sandrine ^a   Frotscher, Martin ^a   Hartmann, Rolf W ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c Institute of Physiological Chemistry   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)BENZENE SULFONAMIDE; 4 INDOLYLSULFONAMIDE; 4,5 DIBROMO N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)THIOPHENE 2 SULFONAMIDE; 5 CHLORO N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)THIOPHENE 2 SULFONAMIDE; METHYL 5 (N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)SULFAMOYL) 4 METHOXYTHIOPHENE 3 CARBOXYLATE; N (3 (2 (HYDROXY) 6 (3 (HYDROXY)PHENYL)NAPHTHALEN 1 YL)PHENYL) 2 METHYLBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 2 FLUOROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 2 NITROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 2,2,2 TRIFLUORO ETHANESULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 2,4 DINITROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 3 CYANOBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 3 FLUOROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 3 HYDROXYBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 3 METHYLBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 3 NITROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 4 BROMO 2 TRIFLUORO METHOXYBENZENESULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 4 BROMO 2,5 FLUOROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 4 CYANOBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 4 FLUOROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 4 HYDROXYBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 4 METHYLBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 4 NITROBENZENE SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL) 5 (2 (METHYLTHIO)PYRIMIDIN 4 YL)THIOPHENE 2 SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)BENZENESULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)BENZO[D]THIAZOLE 6 SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)QUINOLIN 6 SULFONAMIDE; N (3 (2 HYDROXY 6 (3 HYDROXYPHENYL)NAPHTHALEN 1 YL)PHENYL)THIOPHENE 2 SULFONAMIDE; N (4 (N (3 (2 (HYDROXY) 6 (3 (HYDROXY)PHENYL)NAPHTHALEN 1 YL)PHENYL)SULFAMOYL)PHENYL)ACETAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CALLITHRIX; CELL ACTIVITY; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; ENDOMETRIOSIS; HUMAN; IC 50; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 84859791222     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201735j     Document Type: Article

References (68)

1. Miyoshi, Y.; Ando, A.; Shiba, E.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers Int. J. Cancer 2001, 94 (5) 685-689
2. Jansson, A. 17beta-hydroxysteroid dehydrogenase enzymes and breast cancer J. Steroid Biochem. Mol. Biol. 2009, 144 (1-2) 64-67
3. Blomquist, C. H.; Bonenfant, M.; McGinley, D. M.; Posalaky, Z.; Lakatua, D. J.; Tuli-Puri, S.; Bealka, D. G.; Tremblay, Y. Androgenic and estrogenic 17beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: Evidence for the type 1, 2 and 5 isoforms J. Steroid Biochem. Mol. Biol. 2002, 81 (4-5) 343-351
4. Smuc, T.; Hevir, N.; Ribič-Pucelj, M.; Husen, B.; Thole, H.; Rizner, T. L. Disturbed estrogen and progesterone action in ovarian endometriosis Mol. Cell. Endocrinol. 2009, 301 (1-2) 59-64
5. Dizerega, G. S.; Barber, D. L.; Hodgen, G. D. Endometriosis: Role of ovarian steroids in initiation, maintenance and suppression Fertil. Steril. 1980, 33 (6) 649-653
6. Saloniemi, T.; Jarvensivu, P.; Koskimies, P.; Jokela, H.; Lamminen, T.; Ghaem-Maghami, S.; Dina, R.; Damdimopoulou, P.; Makela, S.; Perheentupa, A.; Kujari, H.; Brosens, J.; Poutanen, M. Novel Hydroxysteroid (17beta) Dehydrogenase 1 Inhibitors Reverse Estrogen-Induced Endometrial Hyperplasia in Transgenic Mice Am. J. Pathol. 2010, 176 (3) 1443-1451
7. Kasai, T.; Shozu, M.; Murakami, K.; Segawa, T.; Shinohara, K.; Nomura, K.; Inoue, M. Increased Expression of Type I 17β-Hydroxysteroid Dehydrogenase Enhances in Situ Production of Estradiol in Uterine Leiomyoma J. Clin. Endocrinol. Metab. 2004, 89 (11) 5661-5668
8. Adamo, V.; Iorfida, M.; Montalto, E.; Festa, V.; Garipoli, C.; Scimone, A.; Zanghi, M.; Caristi, N. Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients Ann. Oncol. 2007, 18, 53-57
9. Miller, W. R.; Bartlett, J. M.; Canney, P.; Verrill, M. Hormonal therapy for postmenopausal breast cancer: The science of sequencing Breast Cancer Res. Treat. 2007, 103 (2) 149-160
10. Bush, N. J. Advances in hormonal therapy for breast cancer Semin. Oncol. Nurs. 2007, 23 (1) 46-54
11. Gunnarsson, C.; Hellqvist, E.; Stål, O. 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer Br. J. Cancer 2005, 92 (3) 547-552
12. Šmuc, T.; Pucelj Ribič, M.; Šinkovec, J.; Husen, B.; Thole, H.; Lanišnik Rižner, T. Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis Gynecol. Endocrinol. 2007, 23 (2) 105-111
13. Baston, E.; Palusczak, A.; Hartmann, R. W. 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: Synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2 Eur. J. Med. Chem. 2000, 35 (10) 931-940
14. Picard, F.; Baston, E.; Reichert, W.; Hartmann, R. W. Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2 Bioorg. Med. Chem. 2000, 8 (6) 1479-1487
15. Xu, K.; Al-Soud, Y. A.; Wetzel, M.; Hartmann, R. W.; Marchais- Oberwinkler, S. Triazole ring-opening leads to the discovery of potent nonsteroidal 17beta-hydroxysteroid dehydrogenase type 2 inhibitors Eur. J. Med. Chem. 2011, 46 (12) 5978-5990
16. Wetzel, M.; Marchais-Oberwinkler, S.; Perspicace, E.; Möller, G.; Adamski, J.; Hartmann, R. W. Introduction of an Electron Withdrawing Group on the Hydroxyphenylnaphthol Scaffold Improves the Potency of 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors J. Med. Chem. 2011, 54 (21) 7547-7557
17. Wetzel, M.; Marchais-Oberwinkler, S.; Hartmann, R. W. 17beta-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold Bioorg. Med. Chem. 2011, 19 (2) 807-815
18. Wetzel, M.; Gargano, E. M.; Hinsberger, S.; Marchais-Oberwinkler, S.; Hartmann, R. W. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD2) inhibitors for the treatment of osteoporosis Eur. J. Med. Chem. 2012, 47, 1-17
19. Xu, K.; Wetzel, M.; W. Hartmann, R.; Marchais-Oberwinkler, S. Synthesis and Biological Evaluation of Spiro-lactones as Inhibitors of 17-Hydroxysteroid Dehydrogenase Type 2 (17-HSD2) Lett. Drug Des. Discovery 2011, 8 (5) 406-421
20. Brožic, P.; Lanišnik Rižner, T.; Gobec, S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Curr. Med. Chem. 2008, 15, 137-150 and references therein
21. Poirier, D. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases Anticancer Agents Med. Chem. 2009, 9, 642-660 and references therein
22. Poirier, D. Inhibitors of 17 beta-hydroxysteroid dehydrogenases Curr. Med. Chem. 2003, 10 (6) 453-477 and references therein
23. Brozic, P.; Kocbek, P.; Sova, M.; Kristl, J.; Martens, S.; Adamski, J.; Gobec, S.; Lanisnik Rizner, T. Flavonoids and cinnamic acid derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Mol. Cell. Endocrinol. 2009, 301, 229-234
24. Karkola, S.; Lilienkampf, A.; Wähälä, K. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking ChemMedChem 2008, 3, 461-472
25. Messinger, J.; Hirvelä, L.; Husen, B.; Kangas, L.; Koskimies, P.; Pentikäinen, O.; Saarenketo, P.; Thole, H. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Mol. Cell. Endocrinol. 2006, 248 (1-2) 192-198
26. Lilienkampf, A.; Karkola, S.; Alho-Richmond, S.; Koskimies, P.; Johansson, N.; Huhtinen, K.; Vihko, K.; Wähälä, K. Synthesis and Biological Evaluation of 17beta-Hydroxysteroid Dehydrogenase Type 1 (17beta-HSD1) Inhibitors Based on a Thieno[2,3-d]pyrimidin-4(3H)-one Core J. Med. Chem. 2009, 52 (21) 6660-6671
27. Gobbi, S.; Cavalli, A.; Negri, M.; Schewe, K. E.; Belluti, F.; Piazzi, L.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Imidazolylmethylbenzophenones as Highly Potent Aromatase Inhibitors J. Med. Chem. 2007, 50 (15) 3420-3422
28. Cavalli, A.; Bisi, A.; Bertucci, C.; Rosini, C.; Paluszcak, A.; Gobbi, S.; Giorgio, E.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Hartmann, R. W.; Recanatini, M. Enantioselective Nonsteroidal Aromatase Inhibitors Identified through a Multidisciplinary Medicinal Chemistry Approach J. Med. Chem. 2005, 48 (23) 7282-7289
29. Leroux, F.; Hutschenreuter, T. U.; Charrière, C.; Scopelliti, R.; Hartmann, R. W. N-(4-Biphenylmethyl)imidazoles as Potential Therapeutics for the Treatment of Prostate Cancer: Metabolic Robustness Due to Fluorine Substitution? Helv. Chim. Acta 2003, 86 (7) 2671-2686
30. Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. Effects of novel 17alpha±-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo J. Steroid Biochem. Mol. Biol. 2003, 84 (5) 555-562
31. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Mendieta, M. A. E. P.-B.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha±-hydroxylase- 17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure Bioorg. Med. Chem. 2008, 16 (4) 1992-2010
32. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming Undesirable CYP1A2 Inhibition of Pyridylnaphthalene-Type Aldosterone Synthase Inhibitors: Influence of Heteroaryl Derivatization on Potency and Selectivity J. Med. Chem. 2008, 51 (16) 5064-5074
33. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel Aldosterone Synthase Inhibitors with Extended Carbocyclic Skeleton by a Combined Ligand-Based and Structure-Based Drug Design Approach J. Med. Chem. 2008, 51 (19) 6138-6149
34. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In Vivo Active Aldosterone Synthase Inhibitors with Improved Selectivity: Lead Optimization Providing a Series of Pyridine Substituted 3,4-Dihydro-1H-quinolin- 2-one Derivatives J. Med. Chem. 2008, 51 (24) 8077-8087
35. Hille, U. E.; Zimmer, C.; Haupenthal, J.; Hartmann, R. W. Optimization of the First Selective Steroid-11beta-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases ACS Med. Chem. Lett. 2011, 2 (8) 559-564
36. Hille, U. E.; Zimmer, C.; Vock, C. A.; Hartmann, R. W. First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases ACS Med. Chem. Lett. 2010, 2 (1) 2-6
37. Bey, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Werth, R.; Oster, A.; Algul, O.; Neugebauer, A.; Hartmann, R. W. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases Bioorg. Med. Chem. 2008, 16, 6423-6435
38. Bey, E.; Marchais-Oberwinkler, S.; Werth, R.; Negri, M.; Al-Soud, Y. A.; Kruchten, P.; Oster, A.; Frotscher, M.; Birk, B.; Hartmann, R. W. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes and aza-benzenes as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) J. Med. Chem. 2008, 51, 6725-6739
39. Al-Soud, Y. A.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Werth, R.; Kruchten, P.; Frotscher, M.; Hartmann, R. W. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1 and type 2 Mol. Cell. Endocrinol. 2009, 301, 212-215
40. Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and benzenes: Influence of additional substituents on 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitory activity and selectivity J. Med. Chem. 2009, 52, 6724-6743
41. Kruchten, P.; Werth, R.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells J. Steroid Biochem. Mol. Biol. 2009, 114, 200-206
42. Kruchten, P.; Werth, R.; Marchais-Oberwinkler, S.; Bey, E.; Ziegler, E.; Oster, A.; Frotscher, M.; Hartmann, R. W. Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations C. R. Chim. 2009, 12, 1110-1116
43. Oster, A.; Klein, T.; Werth, R.; Kruchten, P.; Bey, E.; Negri, M.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity Bioorg. Med. Chem. 2010, 18, 3494-3505
44. Oster, A.; Hinsberger, S.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bicyclic Substituted Hydroxyphenylmethanones as Novel Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) for the Treatment of Estrogen-Dependent Diseases J. Med. Chem. 2010, 53 (22) 8176-8186
45. Oster, A.; Klein, T.; Henn, C.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bicyclic Substituted Hydroxyphenylmethanone Type Inhibitors of 17 β-Hydroxysteroid Dehydrogenase Type 1 (17 β-HSD1): The Role of the Bicyclic Moiety ChemMedChem 2011, 6 (3) 476-487
46. Frotscher, M.; Ziegler, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Neugebauer, A.; Fetzer, L.; Scherer, C.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Design, synthesis and biological evaluation of (hydroxyphenyl)-naphthalene and quinoline derivatives: Potent and selective non steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 2008, 51, 2158-2169
47. Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Ziegler, E.; Neugebauer, A.; Bhoga, U. D.; Bey, E.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Substituted 6-phenyl-2-naphthols. Potent and selective non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): Design, synthesis, biological evaluation and pharmacokinetics J. Med. Chem. 2008, 51, 4685-4698
48. Marchais-Oberwinkler, S.; Frotscher, M.; Ziegler, E.; Werth, R.; Kruchten, P.; Messinger, J.; Thole, H.; Hartmann, R. W. Structure-activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors Mol. Cell. Endocrinol. 2009, 301, 205-211
49. Marchais-Oberwinkler, S.; Wetzel, M.; Ziegler, E.; Kruchten, P.; Werth, R.; Henn, C.; Hartmann, R. W.; Frotscher, M. New Drug-Like Hydroxyphenylnaphthol Steroidomimetics As Potent and Selective 17beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Estrogen-Dependent Diseases J. Med. Chem. 2011, 54 (2) 534-547
50. Husen, B.; Huhtinen, K.; Poutanen, M.; Kangas, L.; Messinger, J.; Thole, H. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme Mol. Cell. Endocrinol. 2006, 248 (1-2) 109-113
51. Husen, B.; Huhtinen, K.; Saloniemi, T.; Messinger, J.; Thole, H. H.; Poutanen, M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts Endocrinology 2006, 147 (11) 5333-5339
52. Grummer, R.; Schwarzer, F.; Bainczyk, K.; Hess-Stumpp, H.; Regidor, P. A.; Schindler, A. E.; Winterhager, E. Peritoneal endometriosis: Validation of an in-vivo model Hum. Reprod. 2001, 16 (8) 1736-1743
53. Lamminen, T.; Saloniemi, T.; Huhtinen, K.; Koskimies, P.; Messinger, J.; Husen, B.; Thole, H.; Poutanen, M. In vivo mouse model for analysis of hydroxysteroid (17beta) dehydrogenase 1 inhibitors Mol. Cell. Endocrinol. 2009, 301 (1-2) 158-162
54. Einspanier, A.; Lieder, K.; Bruns, A.; Husen, B.; Thole, H.; Simon, C. Induction of endometriosis in the marmoset monkey (Callithrix jacchus) Mol. Hum. Reprod. 2006, 12 (5) 291-299
55. Klein, T.; Henn, C.; Negri, M.; Frotscher, M. Structural Basis for Species Specific Inhibition of 17beta-Hydroxysteroid Dehydrogenase Type 1 (17beta-HSD1): Computational Study and Biological Validation PLoS ONE 2011, 6 (8) e22990
56. Lucas, S.; Negri, M.; Heim, R.; Zimmer, C.; Hartmann, R. W. Fine-Tuning the Selectivity of Aldosterone Synthase Inhibitors: Structure Activity and Structure Selectivity Insights from Studies of Heteroaryl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-one Derivatives J. Med. Chem. 2011, 54 (7) 2307-2319
57. Milewich, L.; Garcia, R. L.; Gerrity, L. W. 17beta-Hydroxysteroid oxidoreductase: A ubiquitous enzyme. Interconversion of estrone and estradiol-17beta in BALBc mouse tissues Metabolism 1985, 34 (10) 938-944
58. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties J. Med. Chem. 2000, 43 (20) 3714-3717
59. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates J. Med. Chem. 2002, 45 (12) 2615-2623
60. Wilson, D. P.; Wan, Z.-K.; Xu, W.-X.; Kirincich, S. J.; Follows, B. C.; Joseph-McCarthy, D.; Foreman, K.; Moretto, A.; Wu, J.; Zhu, M.; Binnun, E.; Zhang, Y.-L.; Tam, M.; Erbe, D. V.; Tobin, J.; Xu, X.; Leung, L.; Shilling, A.; Tam, S. Y.; Mansour, T. S.; Lee, J. Structure-Based Optimization of Protein Tyrosine Phosphatase 1B Inhibitors: From the Active Site to the Second Phosphotyrosine Binding Site J. Med. Chem. 2007, 50 (19) 4681-4698
61. Bhatt, M. V.; Kulkarni, S. U. Cleavage of Ethers Synthesis 1983, 249-282
62. Felix, A. M. Cleavage of protecting groups with boron tribromide J. Org. Chem. 1974, 39 (10) 1427-1429
63. Qiu, W.; Campbell, R. L.; Gangloff, A.; Dupuis, P.; Boivin, R. P.; Tremblay, M. R.; Poirier, D.; Lin, S.-X. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity FASEB J. 2002, 16 (13) 1829-1831
64. + J. Mol. Biol. 1993, 234 (1) 242-244
65. Lin, S.-X.; Yang, F.; Jin, J. Z.; Breton, R.; Zhu, D. W.; Luu-The, V.; Labrie, F. Subunit identity of the dimeric 17beta-hydroxysteroid dehydrogenase from human placenta J. Biol. Chem. 1992, 267 (23) 16182-16187
66. Sam, K. M.; Auger, S.; Luu-The, V.; Poirier, D. Steroidal spiro-gamma-lactones that inhibit 17beta-hydroxysteroid dehydrogenase activity in human placental microsomes J. Med. Chem. 1995, 38 (22) 4518-4528
67. Sam, K. M.; Boivin, R. P.; Tremblay, M. R.; Auger, S.; Poirier, D. C16 and C17 derivatives of estradiol as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: Chemical synthesis and structure-activity relationships Drug Des. Discovery 1998, 15 (3) 157-180
68. Zimmermann, J.; Liebl, R.; von Angerer, E. 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha J. Steroid Biochem. Mol. Biol. 2005, 94 (1-3) 57-66